EJNMMI Research (Apr 2024)

Non-invasive quantification of 18F-florbetaben with total-body EXPLORER PET

  • Emily Nicole Holy,
  • Elizabeth Li,
  • Anjan Bhattarai,
  • Evan Fletcher,
  • Evelyn R. Alfaro,
  • Danielle J. Harvey,
  • Benjamin A. Spencer,
  • Simon R. Cherry,
  • Charles S. DeCarli,
  • Audrey P. Fan

DOI
https://doi.org/10.1186/s13550-024-01104-7
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background Kinetic modeling of 18F-florbetaben provides important quantification of brain amyloid deposition in research and clinical settings but its use is limited by the requirement of arterial blood data for quantitative PET. The total-body EXPLORER PET scanner supports the dynamic acquisition of a full human body simultaneously and permits noninvasive image-derived input functions (IDIFs) as an alternative to arterial blood sampling. This study quantified brain amyloid burden with kinetic modeling, leveraging dynamic 18F-florbetaben PET in aorta IDIFs and the brain in an elderly cohort. Methods 18F-florbetaben dynamic PET imaging was performed on the EXPLORER system with tracer injection (300 MBq) in 3 individuals with Alzheimer’s disease (AD), 3 with mild cognitive impairment, and 9 healthy controls. Image-derived input functions were extracted from the descending aorta with manual regions of interest based on the first 30 s after injection. Dynamic time-activity curves (TACs) for 110 min were fitted to the two-tissue compartment model (2TCM) using population-based metabolite corrected IDIFs to calculate total and specific distribution volumes (VT, Vs) in key brain regions with early amyloid accumulation. Non-displaceable binding potential ( $$ {BP}_{ND})$$ was also calculated from the multi-reference tissue model (MRTM). Results Amyloid-positive (AD) patients showed the highest VT and VS in anterior cingulate, posterior cingulate, and precuneus, consistent with $$ {BP}_{ND}$$ analysis. $$ {BP}_{ND} $$ and VT from kinetic models were correlated (r² = 0.46, P < 2 $$ {e}^{-16})$$ with a stronger positive correlation observed in amyloid-positive participants, indicating reliable model fits with the IDIFs. VT from 2TCM was highly correlated ( $$ {r}^{2}$$ = 0.65, P < 2 $$ {e}^{-16}$$ ) with Logan graphical VT estimation. Conclusion Non-invasive quantification of amyloid binding from total-body 18F-florbetaben PET data is feasible using aorta IDIFs with high agreement between kinetic distribution volume parameters compared to $$ {BP}_{ND} $$ in amyloid-positive and amyloid-negative older individuals.

Keywords